SavedAdd your journal

Journals / Ege Tıp Dergisi / 2021 / Cilt: 60 - Sayı: 1

Analysis of survival and morbidity outcomes after tertiary and quaternary cytoreductive surgeries in recurrent ovarian cancer patients

Rekürren over kanseri hastalarında uygulanan tersiyer ve kuaterner sitoredüksiyon cerrahilerinin sağ kalıma etkisi ve morbiditesi

Seda YÜKSEL ŞİMŞEK
Hüseyin AKILLI
İrem ALYAZICI KÜÇÜKYILDIZ
Ali AYHAN
Pages
20–31
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Overall and median survival times were 66.5±5.1 and 56 months, respectively.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: To analyze the outcomes of tertiary and quaternary cytoreduction surgeries in recurrent ovarian cancer patients.
📊
Key Findings & Data:Results: A hundred and six patients diagnosed with recurrent ovarian cancer between dates February 2007-February 2012 were included into study.
💡
Conclusion & Impact:Overall and median survival times were 66.5±5.1 and 56 months, respectively.
🔬Design:Research Article
📍Scope:2007 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: To analyze the outcomes of tertiary and quaternary cytoreduction surgeries in recurrent ovarian cancer patients. Materials and Methods: Patients’ data were obtained retrospectively from hospital database. Kaplan-Meier method has been used to analyze survival outcomes. Results: A hundred and six patients diagnosed with recurrent ovarian cancer between dates February 2007-February 2012 were included into study. Tertiary and quaternary cytoreduction surgeries have been performed in 47 and 15 patients, respectively. Mean age at diagnosis was 54.1±11.2 years. Median follow up time was 40 months (min.: 4; max.: 130 months). Overall and median survival times were 66.5±5.1 and 56 months, respectively. Overall survival of patients operated for tertiary cytoreduction was significantly longer than survival of patients who had second recurrence but not operated and given chemotherapy only (73.8±7.3 vs 52.0±5.6 months) (p:0.039). Overall survival of platin-sensitive group was longer than platin-resistant group among tertiary cytoreduction group (78.8±8.2 vs 44.4±6.4), (p:0.121). Overall survival of patients operated for fourth time and given chemotherapy only were 63.7±7.5; 62.7±8.3 months respectively (p:0.616). Intraoperative complication rate is around 15% for both tertiary and quaternary cytoreduction. Postoperative complication rate is around 20-25%. The rate of intensive care unit requirement was highest after third and fourth cytoreductive surgeries compared to first and second cytoreduction and this difference was statistically significant (p:

Özet

Amaç: Rekürren over kanseri hastalarında uygulanan tersiyer ve kuaterner sitoredüktif cerrahilerin sağ kalım ve morbidite sonuçlarının incelenmesidir. Gereç ve Yöntem: Hasta kayıtları retrospektif olarak incelenmiştir. Sağ kalım oranlarının tespitinde Kaplan-Meier sağ kalım analizi ve karşılaştırmalar için log-rank testleri kullanılmıştır. Tüm analizlerde anlamlı istatistiki değer p:

🔖

Cite This Article

ŞİMŞEK, S. Y., AKILLI, H., KÜÇÜKYILDIZ, İ. A., AYHAN, A. (2022). Analysis of survival and morbidity outcomes after tertiary and quaternary cytoreductive surgeries in recurrent ovarian cancer patients. Ege Tıp Dergisi, Cilt: 60 - Sayı: 1, 20–31. https://ajindex.com/articles/496092

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Bristow RE. Surgical standards in the management of ovarian cancer. Curr Opin Oncol Sep 2000; 12 (5): 474–80
  2. Chi DS, Franklin CC, Levine DA et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube and primary peritoneal cancer: a change in surgical approach. Women’s Oncol Rev 2004; 4, (4): 263–4. 3. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, and Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials.Cancer 2009; 115 (6): 1234–44
  3. Kapp KS,Kapp DS, Poschauko J et al. The prognostic significance of peritoneal seeding and size of postsurgical residual in patients with stage III epithelial ovarian cancer treated with surgery, chemotherapy, and high-dose radiotherapy. Gynecol Oncol 1999; 74 (3): 400–7
  4. Harter P, Muallem ZM, Buhrmann C et al. Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol 2011;121 (3): 615–9
  5. Muggia FM, Braly PS, Brady MF et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2000; 18 (1): 106–15
  6. Zang RY, Zhang ZY, Li ZT et al. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer. Eur J Surg Oncol 2000, 26 (8): 798–804
  7. Zang RY, Li ZT, Tang J et al. Secondary Cytoreductive Surgery for Patients with Relapsed Epithelial Ovarian Carcinoma: Who Benefits? Cancer 2004; 100 (6): 1152–61
  8. Ayhan A,Gultekin M, Taskiran C et al. The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience. Am J Obstet Gynecol 2006; 194 (1): 49–56
  9. Bristow RE, Puri I and Chi DS. Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis. Gynecol Oncol 2009; 112 (1): 265–74
  10. Onda T, Yoshikawa H, Yasugi T, Yamada M, Matsumoto K, and Taketani Y. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: Proposal for patients selection. Br J Cancer 2005; 92 (6): 1026–32
  11. Chi DS, McCaughty K, Diaz JP et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006; 106 (9): 1933–9
  12. Bickell NA, Egorova N, P